Abstract：
Inflammatory myofibroblastic tumors (IMTs) are rare sarcomas composed of myofibroblastic and fibroblastic cells, accompanied by inflammatory cell infiltration. Many IMTs exhibit clonal rearrangement of anaplastic lymphoma kinase (ALK). We herein report a 56-year-old woman with uterine IMT harboring a thrombospondin-1::ALK fusion that developed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Laboratory data before systemic therapy indicated increased interleukin-6 and severe leukocytosis. The patient was treated with lorlatinib; however, the response duration was approximately two months. Similar case reports need to be compiled and evaluated to elucidate the efficacy of lorlatinib in post-allo-HSCT IMT with ALK rearrangement.
摘要：
炎性肌纤维母细胞瘤（IMT）是由肌纤维母细胞和成纤维细胞组成的罕见肉瘤，伴有炎性细胞浸润。许多IMT表现出间变性淋巴瘤激酶（ALK）的克隆重排。我们在此报告了一名56岁的子宫IMT妇女，该妇女在异基因造血干细胞移植（allo-HSCT）后发生血小板反应蛋白1：：ALK融合。全身治疗前的实验室数据显示白细胞介素6和严重的白细胞增多。患者接受了氯拉替尼治疗；然而，应答持续时间约为2个月.需要汇编和评估类似的病例报告，以阐明氯拉替尼在ALK重排后allo-HSCTIMT中的疗效。
